NZ757965A - Liquid formulation of anti-tnf alpha antibody - Google Patents

Liquid formulation of anti-tnf alpha antibody

Info

Publication number: NZ757965A
Authority: NZ; New Zealand
Prior art keywords: formulation; adalimumab; formulations; arginine; concentration
Prior art date: 2017-03-16

Application number

NZ757965A

Other languages

English (en)

Inventor

Sora Yun

Youn Kyung Ko

Jin Eon So

Original Assignee

Lg Chemical Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-16

Filing date

2018-03-16

Publication date

2022-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ757965(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-03-16 Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd

2022-07-01 Publication of NZ757965A publication Critical patent/NZ757965A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)

NZ757965A 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody NZ757965A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20170033188		2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr)	2017-03-16	2018-03-16	Formulation liquide d'anticorps anti-tnf alpha

Publications (1)

Publication Number	Publication Date
NZ757965A true NZ757965A (en)	2022-07-01

Family

ID=63522490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ757965A NZ757965A (en)	2017-03-16	2018-03-16	Liquid formulation of anti-tnf alpha antibody

Country Status (14)

Country	Link
JP (2)	JP7109849B2 (fr)
KR (2)	KR20180106974A (fr)
CN (1)	CN110621303A (fr)
AU (1)	AU2018236651B2 (fr)
CO (1)	CO2019010860A2 (fr)
MA (1)	MA46988A1 (fr)
MX (1)	MX2019010895A (fr)
MY (1)	MY197202A (fr)
NZ (1)	NZ757965A (fr)
PH (1)	PH12019502075A1 (fr)
RU (1)	RU2756619C2 (fr)
UA (1)	UA123847C2 (fr)
WO (1)	WO2018169348A1 (fr)
ZA (1)	ZA201906696B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN120241997A (zh) *	2019-02-18	2025-07-04	伊莱利利公司	治疗性抗体制剂
EP3941521A1 (fr) *	2019-03-18	2022-01-26	Alvotech HF	Formulations aqueuses d'anticorps anti-tnf-alpha à des concentrations élevées
TW202519263A (zh) *	2019-03-21	2025-05-16	美商再生元醫藥公司	含有抗il-33抗體之穩定調配物
EP4108258A4 (fr) *	2020-02-20	2024-03-06	Bio-Thera Solutions, Ltd.	Préparation d'anticorps anti-tnf-alpha, sa méthode de préparation et son utilisation
CA3187322A1 (fr) *	2020-07-13	2022-01-20	Merck Patent Gmbh	Excipients reducteurs de viscosite et leurs combinaisons pour formulations de proteines hautement concentrees

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8821865B2 (en) *	2010-11-11	2014-09-02	Abbvie Biotechnology Ltd.	High concentration anti-TNFα antibody liquid formulations
UY34105A (es) *	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
KR101730694B1 (ko) *	2012-03-07	2017-04-27	카딜라 핼쓰캐어 리미티드	TNF-α 항체의 약제학적 제형
PE20191815A1 (es) *	2012-09-07	2019-12-27	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab
CN105051064A (zh) *	2013-01-24	2015-11-11	葛兰素史克知识产权开发有限公司	抗TNF-α抗原结合蛋白
UY35460A (es) *	2013-03-15	2014-10-31	Bayer Healthcare Llc	Formulaciones de anticuerpos anti-receptor de prolactina
WO2015134406A1 (fr) *	2014-03-03	2015-09-11	La Jolla Biologics, Inc.	Préparations aqueuses stables de protéine recombinée
US10688187B2 (en) *	2014-04-02	2020-06-23	Intas Pharmaceuticals Ltd.	Liquid pharmaceutical composition of adalimumab
EP3050557A1 (fr) *	2014-05-23	2016-08-03	Ares Trading S.A.	Composition pharmaceutique liquide
US9821059B2 (en) *	2014-10-17	2017-11-21	Alteogen Inc.	Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) *	2014-10-28	2016-05-30	Richter Gedeon Nyrt	Gyógyászati TNFalfa ellenes antitest készítmény
AR103544A1 (es) *	2015-01-28	2017-05-17	Mabxience S A	FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
WO2016162819A1 (fr) *	2015-04-07	2016-10-13	Lupin Limited	Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

2018
- 2018-03-16 MX MX2019010895A patent/MX2019010895A/es unknown
- 2018-03-16 JP JP2019551275A patent/JP7109849B2/ja active Active
- 2018-03-16 RU RU2019130728A patent/RU2756619C2/ru active
- 2018-03-16 NZ NZ757965A patent/NZ757965A/en unknown
- 2018-03-16 KR KR1020180031016A patent/KR20180106974A/ko not_active Ceased
- 2018-03-16 AU AU2018236651A patent/AU2018236651B2/en active Active
- 2018-03-16 UA UAA201909838A patent/UA123847C2/uk unknown
- 2018-03-16 CN CN201880031705.6A patent/CN110621303A/zh active Pending
- 2018-03-16 WO PCT/KR2018/003097 patent/WO2018169348A1/fr not_active Ceased
- 2018-03-16 MA MA46988A patent/MA46988A1/fr unknown
- 2018-03-16 MY MYPI2019005331A patent/MY197202A/en unknown
2019
- 2019-09-12 PH PH12019502075A patent/PH12019502075A1/en unknown
- 2019-09-30 CO CONC2019/0010860A patent/CO2019010860A2/es unknown
- 2019-10-10 ZA ZA2019/06696A patent/ZA201906696B/en unknown
2020
- 2020-08-05 KR KR1020200098144A patent/KR102342292B1/ko active Active
2022
- 2022-05-06 JP JP2022076654A patent/JP2022097600A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2022097600A (ja)	2022-06-30
WO2018169348A1 (fr)	2018-09-20
AU2018236651A1 (en)	2019-10-31
RU2019130728A3 (fr)	2021-04-16
KR20200096472A (ko)	2020-08-12
PH12019502075A1 (en)	2020-09-14
MY197202A (en)	2023-05-31
CO2019010860A2 (es)	2020-01-17
ZA201906696B (en)	2020-08-26
UA123847C2 (uk)	2021-06-09
KR20180106974A (ko)	2018-10-01
KR102342292B1 (ko)	2021-12-24
JP7109849B2 (ja)	2022-08-01
MX2019010895A (es)	2019-11-05
MA46988A1 (fr)	2020-06-30
CN110621303A (zh)	2019-12-27
RU2019130728A (ru)	2021-04-16
JP2020510079A (ja)	2020-04-02
BR112019019162A2 (pt)	2020-04-14
RU2756619C2 (ru)	2021-10-04
AU2018236651B2 (en)	2020-12-10

Publication	Publication Date	Title
AU2018236651B2 (en)	2020-12-10	Liquid formulation of anti-TNF alpha antibody
AU2007338791B2 (en)	2014-03-13	Stable buffered formulations containing polypeptides
AU2007307107B2 (en)	2011-11-03	Stable antibody formulations
CA2515444C (fr)	2014-04-01	Preparation d'immunoglobuline et son procede de production
CA2976298A1 (fr)	2016-08-18	Formulation liquide stable pour des anticorps monoclonaux
JP2020063261A (ja)	2020-04-23	ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
US20250043027A1 (en)	2025-02-06	Formulation of highly concentrated pharmacologically active antibody
US20250092141A1 (en)	2025-03-20	Vedolizumab formulation
US20210347877A1 (en)	2021-11-11	Pharmaceutical composition comprising antibody, device comprising same, and use thereof
WO2022151940A1 (fr)	2022-07-21	Composition pharmaceutique stable de pertuzumab
BR112019019162B1 (pt)	2024-10-22	Formulação líquida de um anticorpo anti-tnf-a e método parapreparar a formulação líquida
WO2025255300A1 (fr)	2025-12-11	Formulations pour anticorps anti-n3pglu amyloïde bêta
US11236146B2 (en)	2022-02-01	Stable pharmaceutical formulation
AU2014201388C1 (en)	2017-02-02	Stable Buffered Formulations Containing Polypeptides

Legal Events

Date	Code	Title	Description
2022-10-28	PSEA	Patent sealed
2023-02-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2024 BY MARKPRO GLOBAL COMPANY Effective date: 20230221
2024-02-23	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2025 BY MARKPRO GLOBAL COMPANY Effective date: 20240219
2025-02-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2026 BY MARKPRO GLOBAL COMPANY Effective date: 20250221